Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation on Behalf of its Shareholders - UTHR
Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the Board of Directors of United Therapeutics Corporation (“United Therapeutics” or the “Company”) (Nasdaq: UTHR) concerning possible breaches of fiduciary duty and other violations of law.
The investigation concerns actions by United Therapeutics’ Board of Directors that have caused the Company to allegedly engage in improper marketing tactics with regard to its three main drugs, Remodulin, Tyvaso, and Adcirca. The alleged actions are currently the subject of an investigation by the Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS). Shareholders interested in seeking to recover damages on behalf of United Therapeutics and to implement corporate governance measures designed to prevent future misconduct should contact the firm.
If you hold UTHR shares and you would like to discuss your legal rights, you can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to firstname.lastname@example.org.
Please tell us about yourself by completing the form below and we will provide you with additional
information on how to join the Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Tel: (215) 277-5770
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.